Episode 189 - July 17, 2026
Episode
58 min
Read time
2 min
Topics
Health & Wellness, Investing, Fundraising & VC
AI-Generated Summary
Key Takeaways
- ✓Eli Lilly's expansion strategy: Lilly's acquisition of Atai for $2.8B upfront plus $1B CVR signals a deliberate pivot toward disease prevention over treatment, modeled on Silicon Valley playbooks. Investors and competitors should monitor how Lilly's LillyDirect telehealth platform bypasses PBMs, as this direct-to-consumer infrastructure may redefine commercial models across large-cap pharma over the next decade.
- ✓Brepacitinib launch pricing framework: Roivant positions brepacitinib, a JAK1/TYK2 oral inhibitor for dermatomyositis, between two pricing benchmarks: IVIG at roughly $225K annually and VivGuard at approximately $870K gross. Expect net pricing closer to the lower bound. With 20–40% of patients already on off-label JAK inhibitors, physician warehousing creates an accelerated early-adoption dynamic worth tracking at launch.
- ✓China drug innovation shift: BioCentury data shows 40% of new INDs originating from China in 2026 are now first-in-class, up from prior years. Rather than treating this as a geopolitical risk, US biotech teams should evaluate Chinese assets on a case-by-case basis, scrutinizing manufacturing site quality and clinical data reproducibility rather than applying blanket country-level judgments.
- ✓Kalshi clinical trial prediction markets: Kalshi's new venue allows betting on Phase 3 outcomes and regulatory approvals for companies above $500M market cap, with insider trading guardrails. Brepacitinib currently carries an 81% approval probability on the platform. Biotech legal and compliance teams should immediately review whether existing insider trading policies extend to these prediction market instruments for employees.
- ✓ASO tolerability limits tau data interpretation: Biogen and Ionis's Phase 2 dronersen data showed an inverted dose response, with the lower dose outperforming the higher dose on ADAS-Cog and CDR-SB at 76 weeks. This pattern mirrors prior ASO CNS failures and suggests tolerability, not target biology, drove the confounded results. Tau remains a viable target; non-ASO modalities like Arrowhead's BBB-shuttle siRNA deserve closer attention.
What It Covers
Biotech Hangout Episode 189 covers Eli Lilly's $3.8B Atai acquisition, Roivant's upcoming brepacitinib launch for dermatomyositis, China's rising first-in-class drug innovation, Kalshi's clinical trial betting markets, Merck's oral PCSK9 inhibitor approval, and Biogen's mixed Phase 2 tau-targeting ASO data in Alzheimer's disease.
Key Questions Answered
- •Eli Lilly's expansion strategy: Lilly's acquisition of Atai for $2.8B upfront plus $1B CVR signals a deliberate pivot toward disease prevention over treatment, modeled on Silicon Valley playbooks. Investors and competitors should monitor how Lilly's LillyDirect telehealth platform bypasses PBMs, as this direct-to-consumer infrastructure may redefine commercial models across large-cap pharma over the next decade.
- •Brepacitinib launch pricing framework: Roivant positions brepacitinib, a JAK1/TYK2 oral inhibitor for dermatomyositis, between two pricing benchmarks: IVIG at roughly $225K annually and VivGuard at approximately $870K gross. Expect net pricing closer to the lower bound. With 20–40% of patients already on off-label JAK inhibitors, physician warehousing creates an accelerated early-adoption dynamic worth tracking at launch.
- •China drug innovation shift: BioCentury data shows 40% of new INDs originating from China in 2026 are now first-in-class, up from prior years. Rather than treating this as a geopolitical risk, US biotech teams should evaluate Chinese assets on a case-by-case basis, scrutinizing manufacturing site quality and clinical data reproducibility rather than applying blanket country-level judgments.
- •Kalshi clinical trial prediction markets: Kalshi's new venue allows betting on Phase 3 outcomes and regulatory approvals for companies above $500M market cap, with insider trading guardrails. Brepacitinib currently carries an 81% approval probability on the platform. Biotech legal and compliance teams should immediately review whether existing insider trading policies extend to these prediction market instruments for employees.
- •ASO tolerability limits tau data interpretation: Biogen and Ionis's Phase 2 dronersen data showed an inverted dose response, with the lower dose outperforming the higher dose on ADAS-Cog and CDR-SB at 76 weeks. This pattern mirrors prior ASO CNS failures and suggests tolerability, not target biology, drove the confounded results. Tau remains a viable target; non-ASO modalities like Arrowhead's BBB-shuttle siRNA deserve closer attention.
Notable Moment
During the Kalshi discussion, Roivant's CEO revealed that the company held an internal debate about whether its own insider trading policy prohibited employees from betting on brepacitinib's FDA approval on the platform — a compliance grey area that no formal company policy had yet addressed.
Episode Transcript
You're listening to biotech hangout, a live and unedited weekly discussion of all the newest and best in our industry with a group of biotech leaders and experts. I'm Yaron Werber with my cohost today, John Moragonori, who's gonna join in a minute, Sam Faseli and Matt Klein. For more information about our host and guest speaker or to listen to the most recent episode, please go to biotechhangout.com. So we have, literally an action packed, agenda, and I think we're gonna be remiss if we're not gonna start off by talking about the most important news in the world, in the opinion of n of one myself, when that's the upcoming, third and fourth place for the men's World Cup soccer final tomorrow, and then, of course, the World Cup, soccer final on Sunday. And we we we have with us today, we're very lucky to have Sam who, is very close to both England and France. And so, Sam, what's your prediction, first of all, for that game? And I don't know if you wanna share with us who you're actually rooting for. Yeah. Well, remember, Yaron, I I'm kinda perfectly hedged here because I I love both countries very much, and I live in both countries. So, it it it I can't lose. However, I think, if England play the same way they've played with on a with the energy in the Argentina game, then I don't think they they have much of a chance in in surviving this particular one tomorrow night. But, it could be close because France didn't do that well against Spain either. I mean, it was a a pretty pretty abysmal performance with Spain being really solid and tight, so very hard to call. I don't know. I mean, you you probably I don't know. I can't I really can't tell. And to be honest with you, a whole whole bunch of people are saying, what's the point? Who cares? Right? Well, I gotta be honest. So my that's my, you know, my some of my family members, my daughter, my and was asking me, what's the point of the game? And I was like, well, you clearly don't live in The UK or France. I mean, this is still very important game. And, Ken, Matt, what what do you think? I don't know if you have a view. UK or France? I we have a close family friend who's Senegalese and rooted in order for Senegal and then France and then England. And so I've asked her who to bet against, on the basis that maybe I can make some money that way. I don't have an ax in the England versus France game. My son, who's four, has decided he's for Argentina. I'm not sure why, but I guess I'll support his judgments. Yeah. He's a very smart he's a very he's he's he's gonna be an amazing biotech investor if he's supporting Argentina. I like that. He's, as with …
Get the full transcript (10,544 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 55-minute episode.
Get Biotech Hangout summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from Biotech Hangout
Episode 194 - August 28, 2026
Aug 28 · 61 min
The Readout Loud
390: FDA turmoil, election intrigue, AI, and more
Feb 26
More from Biotech Hangout
Episode 193 - August 14, 2026
Aug 14 · 59 min
The Long Run with Luke Timmerman
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
Jul 14
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links.
Tools
- LillyDirectBy guest
by Eli Lilly
“Investors and competitors should monitor how Lilly's LillyDirect telehealth platform bypasses PBMs, as this direct-to-consumer infrastructure may redefine commercial models across large-cap pharma over the next decade.”
“Kalshi's new venue allows betting on Phase 3 outcomes and regulatory approvals for companies above $500M market cap, with insider trading guardrails. Brepacitinib currently carries an 81% approval probability on the platform.”
More from Biotech Hangout
We summarize every new episode. Want them in your inbox?
Similar Episodes
Related episodes from other podcasts
The Readout Loud
Feb 26
390: FDA turmoil, election intrigue, AI, and more
The Long Run with Luke Timmerman
Jul 14
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
Beyond Biotech
Jun 5
Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media
Biotech Bulls & Breakthroughs
May 28
The Hidden Power of One Pivotal Trial That Changed FDA’s Game | Biotech Bulls & Breakthroughs
In Good Company with Nicolai Tangen
May 20
Pfizer CEO: Transforming Drug Discovery, Lessons from China and Leading with Optimism
Explore Related Topics
This podcast is featured in Best Health Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into Biotech Hangout.
Every Monday, we deliver AI summaries of the latest episodes from Biotech Hangout and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime